



## S-1510

## Caerulein ELISA [UniProt: P86486]

Caerulein is a ten amino acid oligopeptide that stimulates smooth muscle and increases digestive secretions. It is similar in action and composition to cholecystokinin and stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. Caerulein is used in paralytic ileus and as diagnostic aid in pancreatic malfunction. It is used to induce pancreatitis in experimental animal models

This ELISA was developed with serum from rabbits immunized with Caerulein coupled to a carrier protein.

## TECHNICAL AND ANALYTICAL CHARACTERISTICS

Lot number: A14819

Host species: Rabbit IgG

Quantity: 96 tests

**Format:** Formulated for extracted samples (EIAH type).

**Shelf-life:** One year from production date. Store refrigerated at 4° - 8°C.

**Applications:** This ELISA has been validated with the included reagents. It is intended

to be used with appropriately extracted samples (original protocol III,

Std.Ab1hr.Bt). For research use only.

Please see www.bma.ch for protocols and general information.

Range: 0-25ng/ml Average IC50: 0.6ng/ml

**Immunogen:** Synthetic peptide H- Pyr-Gln-Asp-Tyr(SO<sub>3</sub>H)-Thr-Gly-Trp-Met-Asp-Phe-

NH<sub>2</sub> coupled to carrier protein.


## **Cross-Reactivity:**

PEPTIDE: %:

Caerulein 100

Cholecystokinin Octapeptide (desulfated) 0

Typical titration curve of Caerulein in a competitive ELISA with this antibody:



Suggested Preparation of Standards		
	ng/ml	Range: 0.02 to 25ng/ml
Stock	1000	
<b>S</b> 1	25.00	Add 25µl Stock + 975µl diluent
S2	6.25	Add 200µl S1 + 600µl diluent
<b>S</b> 3	1.56	Add 200µl S2 + 600µl diluent
S4	0.39	Add 200µl S3 + 600µl diluent
<b>S</b> 5	0.10	Add 200µl S4 + 600µl diluent
S6	0.02	Add 200µl S5 + 600µl diluent
S0	0.00	500µl diluent

This product contains Thimerosal as a preservative and is intended for laboratory use and research purposes only. Purchase of this product does not include authorization to use it in diagnostic or therapeutic applications.

S-1510 EIAH 1.3.2021